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SUMMARY
Mycoplasma gallisepticum (MG) is a persistent, highly transmissible chicken and turkey
pathogen. Infections of the organism can yield signiﬁcant losses in performance and associated
economics to all sectors of the poultry industry. In this paper, potential and realized effects of MG
onthepoultryindustryarediscussedalongwithcurrentlyavailableanddevelopingcontrolmethods.
Available methods of MG control largely include stringent biosecurity and biosurveillance practices
within the turkey and broiler sectors of the poultry industry and live attenuated MG vaccine
strains that are approved for use only within the commercial egg layer industry. Although largely
effective, MG breaks within these industries still occur, demonstrating that further means of control
are required. Alternative means for consideration include bacterins and subunit vaccines, although
their applicability may be limited by associated vaccination protocols. Further means under
consideration include novel live attenuated MG strains and recombinant bacterial and viral species.
Optimally, control methods would be applicable to all poultry and be safe, cost effective, and
efﬁcacious. Current research regarding novel MG vaccines is addressed herein.
Key words: Mycoplasma gallisepticum, vaccine, attenuated vaccine, recombinant vaccine, chronic
respiratory disease, mycoplasmosis, poultry
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DESCRIPTION OF PROBLEM
Mycoplasma gallisepticum (MG) is a major
pathogen of gallineaceous and certain nongalli-
neaceous avian species [1, 2]. This highly trans-
missible organism is the etiologic agent of
chronic respiratory disease in chickens and in-
fectious sinusitis in turkeys. Clinical symptoms
of MG infections in these avian species include
1To whom correspondence should be addressed: jdevans@msa-msstate.ars.usda.gov.
rales, coughing, nasal discharge, sinusitis, and
severe air sac lesions, and consequences of MG
include mortality, carcass condemnation, and re-
duced egg production, hatchability, feed efﬁ-
ciency, and weight gain [2, 3, 4, 5, 6]. Due
to the substantial performance and production
losses, MG has been described as the most eco-
nomically important of the 4 pathogenic Myco-
plasma species affecting poultry, which also in-
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cludeMycoplasma synoviae(chicken and turkey
pathogen), Mycoplasma synoviae (turkey patho-
gen), and Mycoplasma meleagridis (turkey
pathogen) [5, 7, 8]. The annual economic impact
of MG infections in the United States was esti-
mated at between $118 and $150 million for the
layer industry alone in 1994 [4].
In the recent past, the MG outbreaks have
yielded signiﬁcant losses to the poultry industry
[2, 9]. Major outbreaks of MG-induced disease
have been reported in North Carolina [10]. In
addition,theNationalPoultryImprovementPlan
reported [11] that among US breeding ﬂocks
between September 1999 and August 2000, ﬁeld
strains of MG were among mycoplasmas diag-
nosed in ﬂocks totaling 11 egg-type ﬂocks, 34
meat-type ﬂocks, and 22 turkey ﬂocks. These
ﬂocks were conservatively estimated to average
20,000 birds and resulted in signiﬁcant eco-
nomic losses to these industries. Furthermore,
signiﬁcant losses have also been realized by MG
breaks in other sectors of the poultry industry.
For example, one North Carolina broiler com-
pany stated that losses over a 6-mo period in
1999 attributable to MG were conservatively
estimated to be $500,000 to $750,000 [11].
MYCOPLASMA GALLISEPTICUM
PATHOGENESIS
Although MG affects poultry industries
worldwide [12], its pathogenesis toward avian
species is not well understood [13, 14, 15, 16,
17]. Research has indicated that attachment of
MGtospeciﬁctargetcellsviasialicacidresidues
along the respiratory epithelium is required prior
to initiation of the disease processes and that a
complexmultifactorialprocess mediatescytadh-
erence [16, 18].
The pathogenesis of MG is complicated by
an organism’s ability to alter its antigenic proﬁle
and thereby evade the host’s immune system
[19]. Multiple membrane proteins and lipopro-
teins have been characterized with size- or
phase-variant forms that occur at high frequency
and confer phenotypic or antigenic variation to
MG. These proteins and lipoproteins include
PvpA [20, 21] and pMGA (also termed vlhA
[22]) proteins [23, 24]. Additionally, at least 3
other membrane proteins have been identiﬁed
as phase variant [21]. The pathogenicity of MG
may be further complicated by the ability of
MG to penetrate and survive within host cells
resulting in dissemination throughout the host
[14]. Cumulatively, these factors may result in
chronic infection of the host [25, 26].
CURRENT MG CONTROL
STRATEGIES
Current control practices against MG infec-
tion in the United States include intense biosec-
urity and biosurveillance via serological moni-
toring of ﬂocks, MG isolation techniques, and
DNA-baseddetectionmethods[2,27].Although
antibiotics are commonly used to reduce the ef-
fectsofMGinfections,theyhaveprovenineffec-
tive at clearing MG infections [7]. Biosecurity
and biosurveillance measures have been largely
successful at minimizing MG outbreaks among
the breeding stock of the turkey and chicken
industries, in which outbreaks occur only in a
sporadic nature. Furthermore, the “all in-all out”
nature of the meat-type turkey and broiler indus-
tries allows for complete eradication of infected
ﬂocks. In marked contrast, MG occurrence
within the US table egg industry may be consid-
ered endemic,infecting the majority ofthe 276.1
million egg-type laying hens and occurring in
greater than 50% of all egg laying facilities [28].
Within this sector of the industry, eradication of
infected ﬂocks is not feasible due to the extreme
size (>1 million birds) and multiage nature of
the complexes. The MG-infected egg-laying
facilitiesareconsideredinfectedforlifeandmay
serve as reservoirs of infection endangering
other poultry facilities of close proximity.
Because of the unique structure of the layer
industry,analternativeapproachhasbeendevel-
oped to control MG infections in the United
States via live attenuated MG vaccines [29].
Therearecurrently3liveMGvaccinesapproved
and commercially available including F strain
(FVAX-MG, Schering-Plough Animal Health),
6/85 (Mycovac-L, Intervet Inc.), and ts-11 (MG
vaccine, Merial Select). Although each is dis-
tinct, varying in pathogenicity, protection af-
forded, and transmissibility [30], each has been
shown to effectively reduce losses associated
with MG ﬁeld strain challenge [6, 31, 32, 33].
The F strain was the ﬁrst available attenuated
live MG vaccine and has been described as the
most economic in terms of initial cost and appli-
cation-associatedlabor[34].TheFstrainiscapa-
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ble of displacing MG ﬁeld strains [1] and induc-
ing a protective immune response in the vacci-
nated host [35]. The F strain colonizes the
respiratory tract and persists for the life of the
animal. Research has demonstrated that F strain
vaccination of layers limits production losses
associated with MG infection (estimated at 15.7
eggs/hen per 45-wk laying cycle) by approxi-
mately 50% [6]. Interestingly, industry has dem-
onstrated increased egg production in F strain
vaccinated layers as compared with MG-clean
birds [36]. Reductions in mortality [37, 38] and
antibioticrequirements[36]havealsobeenasso-
ciated with F strain vaccination.
Disadvantages of F strain vaccination also
exist. The F strain may induce mild upper respi-
ratory disease, and the response may be height-
ened due to infection with secondary pathogens.
Furthermore, the F strain is transmissible and
pathogenic to turkey and meat-type chicken
ﬂocks [35, 39]. Subsequently, the 2 alternative
MG vaccines, ts-11 and 6/85, were developed.
They were demonstrated to be safer due to re-
duced transmissibility and nonpathogenicity to-
ward turkeys and young broilers and were
widely accepted in vaccination regimens. How-
ever, these strains were shown to be less protec-
tive against ﬁeld strain challenge as compared
with the F strain [40, 41]. Furthermore, the pro-
duction effects of ts-11 and 6/85 on layers have
not been conclusively evaluated.
Historically, vaccination schemes for use in
the layer industry has largely involved treatment
withasinglevaccine.However,newvaccination
technologies, more affordable vaccines, and re-
cent MG breaks in previously vaccinated ﬂocks
have resulted in secondary vaccinations. For ex-
ample, recent MG breaks in layer ﬂocks pre-
viously vaccinated with ts-11 or 6/85 have been
reported and have resulted in revaccination of
these ﬂocks by F strain [34]. Although single
vaccination regimens havebeen widely reﬂected
in research, the microbial and production effects
of utilizing multiple vaccines on a single ﬂock
have not been adequately addressed in current
research. To date, only a single study has been
documented involving multiple vaccinations
within a single ﬂock. However, in this study,
the ﬂocks were treated with the F strain in 1981
and secondarily with ts-11 in 1994 [42], which
is not representative of the current vaccination
schemes.
DEVELOPMENT OF NOVEL
MG VACCINES
Due to the limitations of available live vac-
cines, alternative vaccines are being sought.
Vaccines in their simplest form consist of one
or more puriﬁed subunits (antigens) and are pre-
sented to the host in the presence of an adjuvant,
a substance that enhances the immune response.
More complex vaccine forms may include killed
pathogens or bacterins presented in conjunction
withanadjuvant.Researchregardingtheuseand
further development of MG subunit and bacterin
vaccines has recently been reviewed, and al-
though these vaccine types were generally pro-
tective, the application of the vaccines thus far
developedmaybelimitedduetocostsassociated
with vaccination protocols and overall effective-
ness [43].
Novel live attenuated MG strains (similar to
those currently licensed) may represent another
meanstocontrolMG.Vaccinesofthistypepres-
ent a wide array of relevant antigens to the host
for immune recognition. A novel live attenuated
MGvaccinestraindesignatedK5054iscurrently
being evaluated for control of MG. The strain
was isolated from turkeys exhibiting only mild
clinical signs of MG infection. Subsequent chal-
lenge studies demonstrated that strain K5054
inoculation yielded seroconversion with very
mild lesions in turkeys and protected treated
birds from challenge with a virulent MG strain
[44]. Further studies veriﬁed these ﬁndings in
turkeys and also found strain K5054 to protect
chickens from MG challenge. The strain appears
to preferentially colonize the upper respiratory
tract and effectively reduces airsacculitis in both
ofthese avianspecies[45].Further researchmay
conﬁrmthisstrain asasafeand effectivevaccine
for bothturkeys and chickens. However,a possi-
ble deterrent is the potential of this and other
similarly undeﬁned attenuated strains to revert
to their wild-type pathogenic counterparts.
Recent technologic advances in molecular
biology haveresulted in the developmentof vac-
cines utilizing live organisms to present cloned
pathogenic components to the host [46]. The
use of live organisms as vectors or carriers of
heterologous proteins has gained particular in-
 
a
t
 
O
x
f
o
r
d
 
J
o
u
r
n
a
l
s
 
o
n
 
N
o
v
e
m
b
e
r
 
6
,
 
2
0
1
4
h
t
t
p
:
/
/
j
a
p
r
.
o
x
f
o
r
d
j
o
u
r
n
a
l
s
.
o
r
g
/
D
o
w
n
l
o
a
d
e
d
 
f
r
o
m
 JAPR: Review Article 760
terest in protecting against mucosal pathogens
in which the contribution of the local mucosal
response (IgA) may be important [47]. Numer-
ous bacteria, both gram-positive and gram-nega-
tive,have beeninvestigated ascarriers ofrecom-
binant heterologous antigens, and surface dis-
play of the recombinant proteins is generally
preferable to elicit a strong immune response.
Attenuated and nonpathogenic bacteria may be
usedasvectors;however,nonpathogenicspecies
may be preferred [46].
Recently,moleculartechniquesandinforma-
tion applicable to MG and other closely related
mycoplasma species have progressed and may
be applied to recombinant vaccine development
for MG. These new molecular advancements
include the development of transformation and
expression strategies and the identiﬁcation and
cloning of important MG colonization factors
and surface antigens. Gene transfer, which is
complicated by potent endonucleases [48], has
been accomplished in mycoplasma species via
electroporation[49,50,51],polyethyleneglycol-
mediated transformation [18, 52, 53], and En-
terococcus faecalis-mediated conjugation [54].
ThetransposonsTn916,Tn4001,andderivatives
have proven functional in mycoplasmas [49, 50,
53, 55, 56] and may be applied to mutant con-
struction,geneexpression,proteinfunctionanal-
ysis, and cellular tagging [48]. The MG expres-
sion studies completed to date include the use
of a LacZ fusion protein [57] and a wild type
GapA [18]. In addition, multiple genes encoding
surface antigens and putative colonization fac-
tors have been cloned and characterized. These
include gapA [16], pvpA [20, 21]), mgc1 ([17]),
mgc2 [58], mgc3 [35], crmA [18], and multiple
members of the pMGA gene family [24, 59, 60,
61] (also termed vlhA [22]). Although the use
of some of these genes in a recombinant vaccine
strain would be complicated by variable expres-
sion, they may provide the basis of a safe and
effective MG vaccine.
To this end, a recent attenuated MG strain
that was generated in a laboratory and geneti-
cally modiﬁed is currently being evaluated for
control of MG infections. The MG strain desig-
nated GT5 was created by genetically modifying
a cytadherence-negative laboratorystrain of MG
(gapA, crmA, and hatA) to restore expression of
theprimarycytadhesinGapA[62].Therecombi-
nant MG strain expressed GapA but did not
differinitsabilitytocytadherefromitscytadher-
ence-negative parent strain. An in vivo study
demonstrated that chickens vaccinated with
strain GT5 and subsequently challenged with a
virulent MG strain were protected from MG-
induced disease. Speciﬁcally, the colonization
abilities of the virulent MG strain and the infec-
tion-associated tracheal lesions were reduced
[63].
Live attenuated viruses may also serve as
vehicles for expression of MG antigens for host
immune recognition. To this end, a US-based
company has produced a USDA-approved re-
combinant fowl pox virus containing genes en-
coding for MG antigens for use with chickens
and turkeys. The product, Vectormune FP-MG,
is currently being evaluated for protection
against MG challenge. Data from product ﬁeld
trials indicate that the vaccine yields low rates
of seroconversion and does not induce any MG-
associated clinical signs. Further, initial ﬁeld
studies indicate that chickens vaccinated with
Vectormune FP-MG may be protected from MG
challenge[64].However,researchregardingthis
product is limited, and further research is neces-
sary to determine the level of protection offered
by the vaccine.
Expression of MG antigens in a nonpatho-
genic heterologous bacterial host may provide
an alternative recombinant vaccine. Successful
development of this live recombinant MG vac-
cine requires selection of a proper host and vec-
tor for stability, safety, and effectivity. For sta-
bility, the host and vector should be well main-
tained along the respiratory tract of avian
species. In addition, the host and vector should
be demonstrated as nonpathogenic and ideally
should have a well-understood genetic system
with cloning and expression methods previously
developed. Unfortunately, the nonpathogenic
strains that are known to commonly reside
within the avian respiratory tract have poorly
characterized genetic systems.
Mycoplasmagallinarumisacommonisolate
of avian species [65] and is currently being eval-
uated as a possible host/vector for MG antigen
expression. It has been isolated from the respira-
toryandreproductivetractsofpoultry[66]andis
widely considered nonpathogenic [67]. Further,
research has suggested a beneﬁcial role of M.
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gallinarum toward its avian host. Taylor-Rob-
inson and Cherry [68] found that colonization
of tracheal ring organ cultures by M. gallinarum
protected the ciliated epithelium from MG and
delayed ciliostasis as compared with the un-
treated control. Furthermore, Branton et al. [69]
observedthattheonsetoffattyliverhemorrhagic
syndrome is delayed in M. gallinarum-inocu-
lated birds as compared with uninfected con-
trols. M. gallinarum elicits only a weak immune
CONCLUSIONS AND APPLICATIONS
1. Current means of controlling MG infections among avian species in the United States are
limited. In addition to biosecurity and biosurveillance practices, which are used in all turkey
and chicken industries, only 3 vaccines (live-attenuated MG) have been approved for use (layer
industry only).
2. Other means of control under consideration include the use of subunit or bacterin vaccines may
be limited due to efﬁcacy and associated costs.
3. Two novel live attenuated MG strains have been identiﬁed and are currently being investigated.
In addition, a newly designed recombinant fowl pox virus expressing MG antigens for immune
recognition is available.
4. Research has also been initiated toward the development of novel recombinant vaccines that
use bacterial hosts and vectors to present MG antigens to the avian immune system and may
yield a safe, cost-effective, and efﬁcacious method of MG control applicable to all poultry.
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